A successful formulation development program does not automatically translate into a successful manufacturing process. Moving a product from development through technology transfer and into commercial production introduces challenges that many sponsors underestimate.

While formulation performance may be proven in the laboratory, manufacturing introduces entirely different variables that influence product quality, process robustness, timelines, and cost. Organizations that fail to account for these realities early often encounter delays, increased development costs, additional re-engineering work, and postponed commercialization.

Building manufacturing success begins long before the first production batch. It starts with developing scalable processes that consider long term commercial manufacturing requirements from the outset.

The Biggest Gap Is Often Communication, Not Science

Many organizations treat technology transfer as a formal handoff from development to manufacturing. In practice, successful transfer requires ongoing collaboration between the development and manufacturing teams throughout process development.

Technical reports often capture process parameters, analytical data, and formulation details, but valuable observations made during laboratory development may never become part of the official documentation. Small details that appear insignificant during formulation work can become critical during process scale-up.

A formulation scientist may recognize that a material behaves differently under specific mixing conditions or requires careful monitoring during addition. If those observations remain in laboratory notebooks instead of becoming part of the transfer package, manufacturing teams often spend valuable time rediscovering and addressing the same challenges.

Every unexpected issue introduces additional troubleshooting, process modifications, investigations, and schedule delays.

Laboratory Success Does Not Guarantee Commercial Manufacturing Success

Laboratory development and commercial manufacturing operate under very different conditions.

Small-scale batches allow scientists to make rapid adjustments using flexible laboratory equipment. Commercial manufacturing requires repeatable processes capable of producing consistent product quality across significantly larger batch sizes while meeting quality, operational, and regulatory expectations.

Equipment differences are only one part of the equation.

Manufacturing teams must consider material handling, mixing dynamics, transfer operations, cleaning procedures, process timing, operator safety, and production efficiency. A formulation that performs well in the laboratory may become difficult or even impractical to manufacture if these factors are not considered during early stage  process development.

Processes that rely on extremely tight operating conditions or laboratory-specific techniques often demonstrate limited robustness when transferred to production.

Successful commercial manufacturing begins with development decisions that anticipate commercial realities and support scalable production.

Small Development Decisions Can Create Major Scale-Up Challenges

Many process scale-up challenges originate from assumptions made during early formulation development.

Material selection provides one of the clearest examples.

A hard wax or solid excipient may be easy to remove from a laboratory container when only a few grams are required. Manufacturing may require handling hundreds of kilograms from large drums, introducing entirely new considerations around storage, weighing, transportation, operator safety, and processing.

Likewise, powders that are simple to add manually during laboratory development often require carefully controlled induction into closed manufacturing systems. Static electricity, vacuum levels, addition rates, and mixing sequences all become critical variables that directly influence manufacturing performance.

These challenges rarely indicate that the formulation itself is flawed. More often, they indicate that manufacturability was not considered early enough during process development.

Selecting materials and designing scalable processes from the beginning reduces complexity throughout technology transfer and process scale-up.

Time Is Often the Most Expensive Cost

When development and manufacturing become disconnected, sponsors rarely lose money because a technical problem cannot be solved.

They lose money because solving the problem consumes valuable time.

Unexpected technology transfer and process scale-up challenges frequently require additional development work, engineering studies, process revisions, equipment modifications, supplier changes, and manufacturing investigations. Every additional activity extends project timelines.

For clinical programs, those delays have significant downstream consequences. Clinical materials may not arrive when study sites are ready. Toxicology studies may require rescheduling. Manufacturing campaigns may need to be moved. Supply chains become compressed, requiring expedited materials at significantly higher costs.

For products approaching commercialization, delayed market entry may have an even greater financial impact than the technical issue itself.

Protecting project timelines requires identifying manufacturing risks before production begins, not after.

Manufacturing Should Be Part of Development From Day One

Many technology transfer challenges can be avoided when manufacturing experts become involved during formulation development rather than after the formulation has been finalized.

Early collaboration allows manufacturing specialists to evaluate whether proposed processes can be executed at commercial scale, identify operational risks, recommend scalable processing strategies, and provide practical feedback while development remains flexible.

Instead of discovering limitations during process scale-up, potential issues can be addressed before critical decisions become locked into the formulation.

This collaborative approach creates stronger alignment between formulation scientists, process development, process engineers, technology transfer specialists, and manufacturing teams throughout the product lifecycle.

How CPL Bridges Development and Manufacturing

At CPL, development and manufacturing are not treated as separate functions.

Formulation scientists work directly alongside technology transfer specialists throughout development, ensuring manufacturing considerations influence process design from the earliest stages. Rather than handing projects from one department to another, teams remain engaged as products progress through development, technology transfer, process validation, and commercial manufacturing (For trouble shooting).

CPL’s integrated development model brings together formulation scientists, technology transfer specialists, analytical experts, and manufacturing professionals throughout every stage of development. Manufacturing expertise is incorporated while processes are still being designed, helping identify potential scale-up challenges before they impact project timelines.

Laboratory-scale equipment is selected to reflect the operating principles used during commercial manufacturing whenever possible. This approach allows development teams to better understand how processes will perform at production scales while maintaining continuity between laboratory development and manufacturing operations.

Continuous collaboration helps reduce surprises during technology transfer, strengthens process robustness, and supports more predictable project execution.

Due Diligence Matters When Selecting a CDMO

Selecting a CDMO involves far more than evaluating facilities or equipment.

Sponsors should determine whether a development partner has demonstrated experience moving products from formulation development through technology transfer, process validation, and commercial manufacturing. Cross-functional expertise, integrated project management, and proven scale-up experience often have a greater impact on project success than equipment specifications alone.

Organizations should also evaluate whether technical teams remain involved throughout the project or whether knowledge is transferred through departmental handoffs. Maintaining continuity from development through manufacturing significantly reduces risk while improving communication and execution.

The right partner brings both technical capabilities and practical manufacturing experience to every stage of development.

Building Manufacturing Success Starts Early

The decisions made during formulation development influence every stage that follows. Processes designed without manufacturing in mind often require additional time, resources, and investment before they become commercially viable.

Early collaboration, realistic planning, scalable process development, and continuous communication help reduce technical risk while protecting project timelines and budgets.

CPL works with sponsors throughout formulation development, technology transfer, process scale-up, and commercial manufacturing to help programs move from concept to production with greater confidence and fewer surprises.

Organizations planning their next pharmaceutical development and technology transfer program are encouraged to schedule a meeting with CPL to discuss how an integrated development and manufacturing strategy can support faster, more predictable project outcomes. Additional Expert Resources are available for organizations seeking practical guidance on pharmaceutical development, manufacturing strategy, and technology transfer.